புற்றுநோய் ஆராய்ச்சி ஒன்றுபட்டது கிஂக்டம் சிகிச்சை அலகு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Resistance-busting ICR drug enters clinical trial
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
ICR s resistance-busting drug advances into Phase I trial
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Hits: 772
Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON, MA, USA and TEL AVIV, Israel I January 8, 2021 I ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has committed $40 million in Series A funding to advance Aulos lead molecule from preclinical stage through clinical proof of concept, with human trials expected to start later this year. ATP created Aulos with Biolojic to develop antibodies with unique properties that we believe hold best-in-class promise among IL-2 targeted therapies, said Michael Ehlers, M.D., Ph.D., Chief Scientific Officer of and venture partner at ATP. Biolojic has designed elegant and impressively simple molecules that redirect
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference
BOSTON and TEL AVIV, Israel, Jan. 8, 2021 /PRNewswire/ ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has committed $40 million in Series A funding to advance Aulos lead molecule from preclinical stage through clinical proof of concept, with human trials expected to start later this year.